Danaher Is Down 22% This Year. Is the Masimo Acquisition the Entry Point Investors Have Been Waiting for?

Danaher's stock has fallen 22% this year following its $9.9 billion acquisition of Masimo, which expands the company into clinical patient monitoring. Despite integration risks and a patent dispute with Apple, Danaher reported strong Q1 results with 3% revenue growth and raised 2026 EPS guidance. The company is seeing 30% year-over-year growth in equipment orders, benefiting from a resurgence in life sciences M&A activity. Trading at 20x forward earnings—below its historical average—the stock may represent a buying opportunity if management successfully integrates Masimo.